At Elevation Pharmaceuticals, we often hear from pulmonologists: “We can do better.” Physicians want their patients to comply with their treatment regimens and gain better control of their chronic obstructive pulmonary disease (COPD). Patients experience the limitations of current COPD medications and want easy-to-use therapies that make them feel better and improve their quality of life. This motivates Elevation Pharmaceuticals to develop a pipeline of new aerosol therapies for respiratory diseases including COPD and asthma.
Founded in 2008, Elevation Pharmaceuticals’ team has a successful track record of starting companies and building dedicated teams to develop new drug products that improve patients’ lives. At Elevation, we have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. We are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders – patients, employees, investors and partners.